HRP20161604T1 - Formulacija protutijela protiv il-17 - Google Patents
Formulacija protutijela protiv il-17 Download PDFInfo
- Publication number
- HRP20161604T1 HRP20161604T1 HRP20161604TT HRP20161604T HRP20161604T1 HR P20161604 T1 HRP20161604 T1 HR P20161604T1 HR P20161604T T HRP20161604T T HR P20161604TT HR P20161604 T HRP20161604 T HR P20161604T HR P20161604 T1 HRP20161604 T1 HR P20161604T1
- Authority
- HR
- Croatia
- Prior art keywords
- concentration
- antibody
- seq
- formulation according
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607671P | 2012-03-07 | 2012-03-07 | |
| EP13710214.1A EP2822590B1 (en) | 2012-03-07 | 2013-03-01 | Il-17 antibody formulation |
| PCT/US2013/028516 WO2013134052A1 (en) | 2012-03-07 | 2013-03-01 | Il-17 antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161604T1 true HRP20161604T1 (hr) | 2016-12-30 |
Family
ID=47892018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161604TT HRP20161604T1 (hr) | 2012-03-07 | 2013-03-01 | Formulacija protutijela protiv il-17 |
Country Status (34)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| WO2019027828A1 (en) * | 2017-08-04 | 2019-02-07 | Eli Lilly And Company | DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES |
| WO2019040230A1 (en) | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | TREATMENT OF GENITAL PSORIASIS |
| MX2017016884A (es) * | 2017-12-19 | 2019-06-20 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina anti-tnfa. |
| AU2019388808A1 (en) * | 2018-11-29 | 2021-06-17 | Harbour Biomed Therapeutics Limited | Anti-PD-L1 antibody preparation |
| AU2020225202B2 (en) * | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
| EP4268803A4 (en) * | 2020-12-22 | 2025-04-16 | Bio-Thera Solutions, Ltd. | Stable antibody preparation, preparation method for same, and applications thereof |
| CN119147687B (zh) * | 2024-11-11 | 2025-03-14 | 智翔（上海）医药科技有限公司 | 用于抗白介素17a抗体质量检测的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3808769A1 (en) * | 2005-12-13 | 2021-04-21 | Eli Lilly And Company | Anti-il-17 antibodies |
| AU2007328960B2 (en) * | 2006-12-05 | 2013-01-17 | Crucell Holland B.V. | Liquid anti-rabies antibody formulations |
| US8883151B2 (en) * | 2010-01-15 | 2014-11-11 | Kirin-Amgen, Inc. | IL-17 receptor antibody formulation |
-
2013
- 2013-03-01 UA UAA201409450A patent/UA114620C2/uk unknown
- 2013-03-01 SI SI201330364A patent/SI2822590T1/sl unknown
- 2013-03-01 RS RS20160994A patent/RS55417B1/sr unknown
- 2013-03-01 PT PT137102141T patent/PT2822590T/pt unknown
- 2013-03-01 MX MX2014010710A patent/MX362191B/es active IP Right Grant
- 2013-03-01 DK DK13710214.1T patent/DK2822590T3/en active
- 2013-03-01 EP EP16195503.4A patent/EP3156073A1/en not_active Withdrawn
- 2013-03-01 CN CN201380012452.5A patent/CN104159612B/zh active Active
- 2013-03-01 BR BR112014021308-9A patent/BR112014021308B1/pt active IP Right Grant
- 2013-03-01 JP JP2014560955A patent/JP6117252B2/ja active Active
- 2013-03-01 MY MYPI2014702489A patent/MY167233A/en unknown
- 2013-03-01 SG SG11201404491XA patent/SG11201404491XA/en unknown
- 2013-03-01 PL PL13710214T patent/PL2822590T3/pl unknown
- 2013-03-01 ME MEP-2016-259A patent/ME02565B/me unknown
- 2013-03-01 NZ NZ627648A patent/NZ627648A/en unknown
- 2013-03-01 ES ES13710214.1T patent/ES2610707T3/es active Active
- 2013-03-01 EA EA201491471A patent/EA030742B1/ru not_active IP Right Cessation
- 2013-03-01 EP EP13710214.1A patent/EP2822590B1/en active Active
- 2013-03-01 CA CA2866128A patent/CA2866128C/en active Active
- 2013-03-01 LT LTEP13710214.1T patent/LT2822590T/lt unknown
- 2013-03-01 KR KR1020147024733A patent/KR101653082B1/ko active Active
- 2013-03-01 AU AU2013230490A patent/AU2013230490B2/en active Active
- 2013-03-01 WO PCT/US2013/028516 patent/WO2013134052A1/en active Application Filing
- 2013-03-01 HU HUE13710214A patent/HUE031290T2/hu unknown
- 2013-03-01 HR HRP20161604TT patent/HRP20161604T1/hr unknown
- 2013-03-01 PE PE2014001367A patent/PE20142275A1/es active IP Right Grant
- 2013-03-01 US US14/379,755 patent/US9376491B2/en active Active
-
2014
- 2014-07-30 ZA ZA2014/05654A patent/ZA201405654B/en unknown
- 2014-08-06 TN TNP2014000341A patent/TN2014000341A1/fr unknown
- 2014-08-11 IL IL234053A patent/IL234053B/en active IP Right Grant
- 2014-08-19 CL CL2014002204A patent/CL2014002204A1/es unknown
- 2014-09-02 MA MA37317A patent/MA37317B1/fr unknown
- 2014-09-05 EC ECIEPI201417562A patent/ECSP14017562A/es unknown
- 2014-09-05 PH PH12014501985A patent/PH12014501985B1/en unknown
-
2016
- 2016-06-10 US US15/178,583 patent/US9845353B2/en active Active
- 2016-12-23 CY CY20161101339T patent/CY1118393T1/el unknown
-
2017
- 2017-11-10 US US15/808,939 patent/US10472416B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02565B (me) | Formulacija protutijela protiv il-17 | |
| HRP20241660T1 (hr) | Formulacija protutijela anti-cgrp | |
| JP2015510882A5 (enrdf_load_stackoverflow) | ||
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| JP2019504086A5 (enrdf_load_stackoverflow) | ||
| HRP20221139T1 (hr) | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| HRP20220111T1 (hr) | Protutijela protiv pd-1 | |
| NZ601125A (en) | Antibody formulation and therapeutic regimens | |
| HRP20191199T1 (hr) | Formulacije protutijela anti-prolaktinskog receptora | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| JP2015526440A5 (enrdf_load_stackoverflow) | ||
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| AR086074A1 (es) | Composiciones y metodo para tratar enfermedades autoinmunes | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
| HRP20231456T1 (hr) | Protutijela protiv c5 i njihova upotreba | |
| JP2011219478A5 (enrdf_load_stackoverflow) | ||
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 |